Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 1, 2006
Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinomaLucio Tentori, Carlo Leonetti, Marco Scarsella, et al.
International Journal of Oncology|January 13, 2005
Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumorsLucio Tentori, Carlo Leonetti, Marco Scarsella, et al.
The Lancet. Oncology|February 14, 2012
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trialRavi A Madan, Mahsa Mohebtash, Philip M Arlen, et al.
International Journal of Cancer|January 16, 2013
Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancerNgar-Yee Huen, Alan Lap-Yin Pang, Jo A Tucker, et al.
The Breast Journal|December 24, 2025
Adherence to Aromatase Inhibitor Therapy in Breast Cancer: Insights From a Multicenter Italian StudyMaria Agnese Fabbri, Alberto Fulvi, Matteo Vergati, et al.
Cancer Immunology, Immunotherapy : CII|November 6, 2009
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancerJames L Gulley, Philip M Arlen, Ravi A Madan, et al.
NPJ Breast Cancer|May 29, 2026
Platinum-based neoadjuvant chemotherapy and the predictive role of DNA damage response biomarkers in TNBC: the NeoCarbo studyEriseld Krasniqi, Anna Di Benedetto, Lorena Filomeno, et al.
Cancers|December 17, 2024
Tolerability and Preliminary Outcomes of Adjuvant T-DM1 in HER2-Positive Breast Cancer After Neoadjuvant Therapy: The ATD StudyEriseld Krasniqi, Lorena Filomeno, Teresa Arcuri, et al.
Breast (Edinburgh, Scotland)|May 27, 2025
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitorsRoberta Scafetta, Marco Donato, Carla Gullotta, et al.
The Oncologist|April 17, 2026
Comparative real-world Progression Free Survival of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Patients with Bone MetastasesRoberta Scafetta, Marco Donato, Carla Gullotta, et al.
Pageof 4